(S)-3-tert-butoxycarbonylamino-2,2-dimethyl-butyric acid methyl ester | 499242-68-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (S)-3-tert-butoxycarbonylamino-2,2-dimethyl-butyric acid methyl ester
• 英文别名: methyl (3S)-2,2-dimethyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate
• CAS: 499242-68-1
• 化学式: C₁₂H₂₃NO₄
• 分子量: 245.319
• InChiKey: XLJSFCCSXRZMHQ-QMMMGPOBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (S)-3-tert-butoxycarbonylamino-2,2-dimethyl-butyric acid methyl ester 在 sodium hydroxide 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 氯仿 、 2,2,2-三氟乙醇 为溶剂， 反应 23.0h， 生成 Butanoic acid,3-[[(3S)-3-[[(1,1-dimethylethoxy)carbonyl]amino]-2,2-dimethyl-1-oxobutyl]amino]-2,2-dimethyl-, methyl ester, (3S)-
  参考文献：
  名称：

  摘要：

  The preparation of (S)-beta(2.2.3) -amino acids with two Me groups in the a-position and the side chains of Ala, Val, and Len in the P-position (double methylation of Boc-beta-HAla-OMe, Boc-beta-Val-OMe, and Boc-beta-LeuOMe, Scheme 2) is described. These beta-amino acids and unlabelled as well as specifically C-13- and (15)labelled 2,2-dimethyl-3-amino acid (beta(2.2)-HAib) derivatives have been coupled in solution (Schemes 1, 3 and 4) to give protected (N-Boc, C-OMe), partially protected (N-Boc/C-OH, N-H/C-OMe), and unprotected beta(2.2) - and beta(2.2.3)- hexapeptides, and beta(2.2) and beta(2.2.3)-heptapeptides 1-7. NMR Analyses in solution (Tables 1 and 2, and Figs. 2-4) and in the solid state (2D-MAS NMR measurements of the fully labelled BOC-(beta(2.2)-HAib)(6)-OMe ([C-13(30), N-15(6)]-1e; Fig. 5), and TEDOR/REDOR NMR investigations of mixtures (Fig. 6) of the unlabelled AC-([beta(2.2)-HAib)(7)- OMe (4) and of a labelled derivative ([C-13(4),N-15(2)]-5; Figs. 7- 11, and 19), a molecular-modeling study (Figs. 13 15), and a search in the Cambridge Crystallographic Data Base (Fig. 16) allow the following conclusions: i) there is no evidence for folding (helix or turn) or for aggregation to sheets of the geminally dimethyl substituted peptide chains in solution; ii) there are distinct conformational preferences of the individual beta(2.2) and beta(2.2.3)-amino acid residues: close to eclipsing around the C(O) - C(Me-2(CHR)) bond (tau(1.2)), almost perfect staggering around the C(2)-C(3) ethane bond (tau(2,3)), and antiperiplanar arrangement of H(C3) and H(N) (TIN; Fig. 12) in the solid state; iii) the beta(2,2)-peptides may be part of a turn structure with a ten-membered H-bonded ring; iv) the main structure present in the solid state of F3CCO(beta(2,2) -HAib)(7)-OMe is a nonfolded chain (>30 Angstrom between the termini and >20 Angstrom between the N-terminus and the CH2 group of residue 5) with all C = O bonds in a parallel alignment (+/-10degrees). With these structural parameters, a simple modelling was performed producing three (maybe four) possible chain geometries: one fully extended, two with parallel peptide planes (with zick-zack and crankshaft-type arrangement of the peptide bonds). and (possibly) a fourth with meander-like winding (D-G in Figs. 17 and 18).

  DOI：

  10.1002/1522-2675(200209)85:9<2877::aid-hlca2877>3.0.co;2-w
• 作为产物：
  描述：

  (s)-3-boc-氨基丁酸甲酯 、 碘甲烷 在 正丁基锂 、 二异丙胺 、 lithium diisopropyl amide 、 水 、 氯化铵 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 20.08h， 以39%的产率得到(S)-3-tert-butoxycarbonylamino-2,2-dimethyl-butyric acid methyl ester
  参考文献：
  名称：

  [EN] PYRROLO [2, 3 - B] PYRAZINE - 7 - CARBOXAMIDE DERIVATIVES AND THEIR USE AS JAK AND SYK INHIBITORS
  [FR] DÉRIVÉS DE PYRROLO[2,3-B]PYRAZINE-7-CARBOXAMIDE ET LEUR UTILISATION COMME INHIBITEURS DE JAK ET SYK

  摘要：

  本发明涉及使用式（I）的新型吡咯吡嗪衍生物，其中变量Q和R，R2和R3如本文所述定义，其抑制JAK和SYK并且适用于治疗自身免疫和炎症性疾病。

  公开号：

  WO2011144585A1

文献信息

• Pyrrolopyrazine Kinase Inhibitors
  申请人：Hendricks Robert Than

  公开号：US20110288067A1

  公开（公告）日：2011-11-24

  The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables Q and R, R 2 , and R 3 are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

  本发明涉及使用新型 Formula I 中的吡咯吡嗪衍生物，其中变量 Q 和 R、R2 和 R3 如本文所述定义，这些衍生物抑制 JAK 和 SYK，并用于治疗自身免疫和炎症性疾病。
• PYRROLOPYRAZINE KINASE INHIBITORS
  申请人：Hoffmann-La Roche Inc.

  公开号：US20140155376A1

  公开（公告）日：2014-06-05

  The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables Q and R, R 2 , and R 3 are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

  本发明涉及使用公式I中的新型吡咯吡嗪衍生物，其中变量Q和R，R2和R3的定义如本文所述，它们抑制JAK和SYK，并且对于治疗自身免疫和炎症性疾病是有用的。
• CD Spectra in Methanol ofβ-Oligopeptides Consisting ofβ-Amino Acids with Functionalized Side Chains, with Alternating Configuration, and with Geminal Backbone Substituents - Fingerprints of New Secondary Structures?
  作者：Dieter Seebach、Thierry Sifferlen、Pascal A. Mathieu、Andreas M. Häne、Christoph M. Krell、Daniel J. Bierbaum、Stefan Abele

  DOI：10.1002/1522-2675(20001108)83:11<2849::aid-hlca2849>3.0.co;2-r

  日期：2000.11.8

  beta -Hexa-, beta -hepta-, and beta -nonapeptides, 1-6, which carry functionalized side chains (CO(2)R, CO(2)(-), (CH(2))(4)NH(3)(+), CH(2)-CH=CH(2)) consisting of beta (3)-amino-acid residues of alternating configuration, or which carry geminal substituents in the 2- or 3-positions of all residues, have been synthesized (Schemes 1 - 3), and their CD spectra in MeOH are reported (Figs. 2 - 6). Strong Cotton effects (Theta >10(5)) are indicative of the presence of chiral secondary structures. It is suggested by simple modelling (Fig. 1) that the new beta -peptides should not be able to fold to the familiar 3(14)-helical structures. Still, three of them (3, 4, and 5) give rise to CD spectra matching those of beta -peptides that are known to be present as (M)- or (P)3(14)-helices in MeOH solution. While possible folding motifs (Figs. 3, b, and 7) of the new beta -peptides have been identified in crystal structures, an interpretation of the CD spectra has to be postponed until NMR solution structures become available. A list of all beta -peptides giving rise to CD spectra with a minimum near 215 nm is included (Table).
• PYRROLO [2, 3 - B]PYRAZINE - 7 - CARBOXAMIDE DERIVATIVES AND THEIR USE AS JAK AND SYK INHIBITORS
  申请人：F.Hoffmann-La Roche AG

  公开号：EP2571880A1

  公开（公告）日：2013-03-27
• [EN] PYRROLO [2, 3 - B] PYRAZINE - 7 - CARBOXAMIDE DERIVATIVES AND THEIR USE AS JAK AND SYK INHIBITORS<br/>[FR] DÉRIVÉS DE PYRROLO[2,3-B]PYRAZINE-7-CARBOXAMIDE ET LEUR UTILISATION COMME INHIBITEURS DE JAK ET SYK
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011144585A1

  公开（公告）日：2011-11-24

  The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula (I), wherein the variables Q and R, R2, and R3 are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

  本发明涉及使用式（I）的新型吡咯吡嗪衍生物，其中变量Q和R，R2和R3如本文所述定义，其抑制JAK和SYK并且适用于治疗自身免疫和炎症性疾病。